(Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant ... treatment options for patients with LVADs and rare cardiovascular ...
Good afternoon, ladies and gentlemen, and welcome to the NRx Pharmaceuticals third-quarter 2024 earnings conference call. (Operator Instructions) This call is being recorded on Monday, November 18, ...